Clindacyl 300 mg Tablets for Dogs

Երկիր: Իռլանդիա

Լեզու: անգլերեն

Աղբյուրը: HPRA (Health Products Regulatory Authority)

Ակտիվ բաղադրիչ:

Clindamycin (as clindamycin hydrochloride)

Հասանելի է:

Chanelle Pharmaceuticals Manufacturing Limited

ATC կոդը:

QJ01FF01

INN (Միջազգային անվանումը):

Clindamycin (as clindamycin hydrochloride)

Դոզան:

300 mg/tablet

Դեղագործական ձեւ:

Tablet

Ռեկվիզորի տեսակը:

POM: Prescription Only Medicine as defined in relevant national legislation

Թերապեւտիկ տարածք:

clindamycin

Լիազորման կարգավիճակը:

Authorised

Հաստատման ամսաթիվը:

2008-07-30

Ապրանքի հատկությունները

Health Products Regulatory Authority
25 January 2022
CRN00CKL3
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Clindacyl 300 mg Tablets for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Clindamycin (as Clindamycin Hydrochloride) 300 mg
EXCIPIENTS:
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet
A plain white to off white tablet with a cross break line on one side.
The tablets can be divided into halves or quarters.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of:
Infected wounds, abscesses and oral cavity/dental infections caused by
or associated with clindamycin-sensitive species of:

_Staphylococcus_ spp.

_Streptococcus_ spp.

_Bacteroides_ spp.

_Fusobacterium _
_necrophorum_

_Clostridium perfringens_
Osteomyelitis

​_Staphylococcus aureus_
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to lincosamides.
Do not administer to rabbits, hamsters, guinea pigs, chinchillas,
horses or ruminants because ingestion of clindamycin by these
species may result in severe gastro-intestinal disturbance.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None known.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
During prolonged therapy of one month or greater, periodic liver and
kidney function tests and blood counts should be
performed. Patients with severe renal and/or hepatic disturbances
accompanied by severe metabolic aberrations should be
dosed with caution and should be monitored by serum examinations
during clindamycin therapy.
Health Products Regulatory Authority
25 January 2022
CRN00CKL3
Page 2 of 4
Whenever possible, the veterinary medicinal product should only be
used based on susceptibility testing.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCTS TO ANIMALS
Wash hands after the administration of the product. Persons with